Skip to main content
Equibles
SRTS logo

SRTS · Sensus Healthcare, Inc. · Metrics

Track SRTS — free

Use SRTS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SRTS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.86 -0.06 (-2.05%) At close · Nov 6 Play latest call Q2 2026 earnings call transcript
Rebalance outlook locked
Market Cap
$46.92M
Shares
16.46M
Volume · Nov 6 102.86K Avg daily vol (3M) 190.68K

SRTS metrics

100 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$2.86
Market cap
$46.92M

Price action

23 metrics
Price change (1W)
+5.4%
Price change (30D)
-0.7%
Price change (3M)
-2.0%
Price change (6M)
-29.0%
Price change (YTD)
-26.6%
Price change (1Y)
-20.9%
Trailing year
Price change (5Y)
-29.3%
52-week high
$5.30
52-week low
$2.69
Change from 52-week high
-44.9%
Change from 52-week low
+8.6%
Annualized volatility
66.5%
Annualized volatility (3M)
59.7%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.1
RSI (14D)
49.5
Price vs SMA 50
-3.2%
Price vs SMA 200
-16.5%
Avg volume (3M)
189,265
Relative volume
0.8
Average dollar volume
$615,402

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
16.46M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
1.9×
reciprocal yield 52.5%
EV / EBITDA
—
EV / EBIT
—
P / sales
2.8×
reciprocal yield 36.1%
P / book
1.3
reciprocal yield 76.0%
FCF yield
-14.4%
TTM · current market cap
Buyback yield
0.6%
P / FCF
—
P / operating cash flow
—
Earnings yield
-31.9%

Historical valuation

8 metrics
P / E historical average (3Y)
24.3×
reciprocal yield 4.1%
P / E historical average (5Y)
24.3×
reciprocal yield 4.1%
EV / revenue historical average (3Y)
1.6×
reciprocal yield 61.3%
EV / revenue historical average (5Y)
2.3×
reciprocal yield 44.4%
EV / EBIT historical average (3Y)
11.7×
reciprocal yield 8.5%
EV / EBIT historical average (5Y)
14.8×
reciprocal yield 6.7%
EV / EBITDA historical average (3Y)
10.8×
reciprocal yield 9.3%
EV / EBITDA historical average (5Y)
10.8×
reciprocal yield 9.3%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
0.6%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
2026-11-12
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
36.4%
Operating margin
-75.7%
Trailing 12 months
Net margin
-88.5%
Gross profit (TTM)
$6.37M
Operating profit (TTM)
−$13.26M
Net income (TTM)
−$15.48M
Trailing 12 months
Diluted EPS (TTM)
$-0.94
FCF margin
-39.8%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$1.07
Gross profit per diluted share (TTM)
$0.39
Operating profit per diluted share (TTM)
$-0.81
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.94
Operating cash flow per diluted share (TTM)
$-0.41
Free cash flow per diluted share (TTM)
$-0.42
Capital expenditures per diluted share (TTM)
$0.01
R&D per diluted share (TTM)
$0.39
Stock compensation per diluted share (TTM)
$0.02
Book value per share
$2.92

Growth

11 metrics
Revenue growth YoY
-68.7%
Year over year
Net income growth YoY
-216.1%
Revenue (TTM)
$17.51M
Trailing 12 months
EPS growth YoY
-214.6%
Shares change YoY
+0.9%
Year over year · more shares
Revenue CAGR (3Y)
-14.9%
Revenue CAGR (5Y)
+23.5%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-42.0%
Return on assets
-37.5%
Debt / equity
0.0
Current ratio
8.7
EBITDA (TTM)
−$12.86M
Free cash flow (TTM)
−$6.97M
Quick ratio
4.4
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$15.19M
Latest balance sheet
Cash & equivalents
$15.19M
Total assets
$41.26M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$6.80M
Capital expenditures (TTM)
$173,000
R&D (TTM)
$6.40M
SG&A (TTM)
$7.51M
Stock compensation (TTM)
$289,000
R&D / revenue
36.6%
Stock compensation / revenue
1.7%

Ownership (13F)

9 metrics
13F filers
40
13F filer change QoQ
-4
Institutional ownership
22.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
5.7%
Private-fund adviser ownership
5.6%
Active holders' share change QoQ
-9.5%
Holder tenure
10.1
Price vs estimated holder cost
-39.7%

Ownership (registered funds)

1 metrics
Index-fund ownership
5.1%

Short interest

3 metrics
Short interest
1.4%
Latest settlement · 14.3 days to cover
Days to cover
14.3d
Short-squeeze score
82 / 100

Insider activity

2 metrics
Net insider buying (90D)
$563,538
Insider-sentiment score
93 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1494891 CUSIP 81728J109 13F (30d) 18 filings 14 filers Visit website Investor relations